CYTOKINETICS, INCORPORATED Net Income (Loss) Available to Common Stockholders, Basic
CYTOKINETICS, INCORPORATED (CYTK) reported Net Income (Loss) Available to Common Stockholders, Basic of $8.44 million for the 3-month period ending 2014-12-31, per its 10-K filed 2015-03-06.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2015-03-06
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for the quarter ending 2014-12-31 was $8.44M, a 29.28% increase year-over-year.
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for the quarter ending 2014-09-30 was -$5.97M.
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for the quarter ending 2014-06-30 was -$8.37M.
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for the quarter ending 2014-03-31 was -$8.74M.
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for fiscal 2014 was -$14.65M.
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for fiscal 2013 was -$33.72M.
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for fiscal 2012 was -$41.68M.
- CYTOKINETICS, INCORPORATED net income (loss) available to common stockholders, basic for fiscal 2011 was -$50.72M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 167 month | Net Income (Loss) Available to Common Stockholders, Basic 170 month | Net Income (Loss) Available to Common Stockholders, Basic 173 month | Net Income (Loss) Available to Common Stockholders, Basic 176 month | Net Income (Loss) Available to Common Stockholders, Basic 179 month | Net Income (Loss) Available to Common Stockholders, Basic 182 month | Net Income (Loss) Available to Common Stockholders, Basic 185 month | Net Income (Loss) Available to Common Stockholders, Basic 188 month | Net Income (Loss) Available to Common Stockholders, Basic 191 month | Net Income (Loss) Available to Common Stockholders, Basic 194 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | $8.44M 10-K · filed 2015-03-06 | $2.47M derived: sum of 2 quarters · filed 2015-03-06 | -$5.90M derived: sum of 3 quarters · filed 2015-03-06 | -$14.65M 10-K · filed 2015-03-06 | ||||||||||
| 2014-09-30 | -$5.97M 10-K · filed 2015-03-06 | -$14.35M derived: sum of 2 quarters · filed 2015-03-06 | -$23.09M 10-Q · filed 2014-11-06 | -$16.56M derived: sum of 4 quarters · filed 2015-03-06 | ||||||||||
| 2014-06-30 | -$8.37M 10-K · filed 2015-03-06 | -$17.12M 10-Q · filed 2014-08-07 | -$10.59M derived: sum of 3 quarters · filed 2015-03-06 | -$23.18M derived: sum of 4 quarters · filed 2015-03-06 | ||||||||||
| 2014-03-31 | -$8.74M 10-K · filed 2015-03-06 | -$2.21M derived: sum of 2 quarters · filed 2015-03-06 | -$14.80M derived: sum of 3 quarters · filed 2015-03-06 | -$29.84M derived: sum of 4 quarters · filed 2015-03-06 | ||||||||||
| 2013-12-31 | $6.53M 10-K · filed 2015-03-06 | -$6.06M derived: sum of 2 quarters · filed 2015-03-06 | -$21.10M derived: sum of 3 quarters · filed 2015-03-06 | -$33.72M 10-K · filed 2015-03-06 | ||||||||||
| 2013-09-30 | -$12.59M 10-K · filed 2015-03-06 | -$27.63M derived: sum of 2 quarters · filed 2015-03-06 | -$40.25M 10-Q · filed 2014-11-06 | -$51.70M derived: sum of 4 quarters · filed 2015-03-06 | -$493.29M 10-Q · filed 2013-11-06 | |||||||||
| 2013-06-30 | -$15.04M 10-K · filed 2015-03-06 | -$27.66M 10-Q · filed 2014-08-07 | -$39.12M derived: sum of 3 quarters · filed 2015-03-06 | -$49.16M derived: sum of 4 quarters · filed 2015-03-06 | -$480.70M 10-Q · filed 2013-08-07 | |||||||||
| 2013-03-31 | -$12.62M 10-K · filed 2015-03-06 | -$24.07M derived: sum of 2 quarters · filed 2015-03-06 | -$34.12M derived: sum of 3 quarters · filed 2015-03-06 | -$44.37M derived: sum of 4 quarters · filed 2015-03-06 | -$465.66M 10-Q · filed 2013-05-08 | |||||||||
| 2012-12-31 | -$11.46M 10-K · filed 2014-03-07 | -$21.50M derived: sum of 2 quarters · filed 2014-03-07 | -$31.75M derived: sum of 3 quarters · filed 2014-03-07 | -$41.68M 10-K · filed 2015-03-06 | -$453.04M 10-K · filed 2013-03-15 | |||||||||
| 2012-09-30 | -$10.04M 10-K · filed 2014-03-07 | -$20.29M derived: sum of 2 quarters · filed 2014-03-07 | -$30.22M 10-Q · filed 2013-11-06 | -$42.10M derived: sum of 4 quarters · filed 2014-03-07 | -$441.59M 10-Q · filed 2012-11-07 | |||||||||
| 2012-06-30 | -$10.25M 10-K · filed 2014-03-07 | -$20.18M 10-Q · filed 2013-08-07 | -$32.05M derived: sum of 3 quarters · filed 2014-03-07 | -$42.69M derived: sum of 4 quarters · filed 2014-03-07 | -$431.54M 10-Q · filed 2012-08-06 | |||||||||
| 2012-03-31 | -$9.93M 10-K · filed 2014-03-07 | -$21.80M derived: sum of 2 quarters · filed 2014-03-07 | -$32.44M derived: sum of 3 quarters · filed 2014-03-07 | -$48.93M derived: sum of 4 quarters · filed 2014-03-07 | -$421.30M 10-Q · filed 2012-05-04 | |||||||||
| 2011-12-31 | -$11.88M 10-K · filed 2013-03-15 | -$22.52M derived: sum of 2 quarters · filed 2013-03-15 | -$39.01M derived: sum of 3 quarters · filed 2013-03-15 | -$50.72M 10-K · filed 2014-03-07 | -$411.37M 10-K · filed 2012-03-13 | |||||||||
| 2011-09-30 | -$10.64M 10-K · filed 2013-03-15 | -$27.13M derived: sum of 2 quarters · filed 2013-03-15 | -$38.84M 10-Q · filed 2012-11-07 | -$50.45M derived: sum of 4 quarters · filed 2013-03-15 | -$399.49M 10-Q · filed 2011-11-04 | |||||||||
| 2011-06-30 | -$16.49M 10-K · filed 2013-03-15 | -$28.20M 10-Q · filed 2012-08-06 | -$39.81M derived: sum of 3 quarters · filed 2013-03-15 | -$52.16M derived: sum of 4 quarters · filed 2013-03-15 | -$388.85M 10-Q · filed 2011-08-04 | |||||||||
| 2011-03-31 | -$11.71M 10-K · filed 2013-03-15 | -$23.32M derived: sum of 2 quarters · filed 2013-03-15 | -$35.67M derived: sum of 3 quarters · filed 2013-03-15 | -$48.81M derived: sum of 4 quarters · filed 2013-03-15 | ||||||||||
| 2010-12-31 | -$11.61M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | -$23.95M derived: sum of 2 quarters · filed 2013-03-15 | -$37.10M derived: sum of 3 quarters · filed 2013-03-15 | -$49.29M 10-K · filed 2013-03-15 | ||||||||||
| 2010-09-30 | -$12.34M 10-Q · filed 2011-11-04 | -$25.48M derived: sum of 2 quarters · filed 2011-11-04 | -$37.67M 10-Q · filed 2011-11-04 | |||||||||||
| 2010-06-30 | -$13.14M 10-Q · filed 2011-08-04 | -$25.33M 10-Q · filed 2011-08-04 | ||||||||||||
| 2009-12-31 | $24.54M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |